Incyte Q3 FY25: where the revenue came from and where it went
The whole income statement of Incyte for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Oct 28, 2025
Revenue$1.37B
+20% year over year
Gross profit$1.27B
93% margin
Operating profit$0.44B
32% margin
Net profit$0.42B
31% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.37 | 100% | +20% |
| Jakafi | 0.79 | 58% | +7% |
| Opzelura | 0.19 | 14% | +35% |
| Product royalty | 0.17 | 13% | +9% |
| Niktimvo | 0.05 | 3% | |
| Other | 0.05 | 3% | |
| Milestone & contract | 0.05 | 3% | +150% |
| Minjuvi/monjuvi | 0.04 | 3% | +34% |
| Iclusig | 0.04 | 3% | +26% |
| Cost of revenue | −0.10 | 7% | |
| Gross profit | 1.27 | 93% margin | +0pp |
| R&D | −0.49 | 36% | −13pp |
| SG&A | −0.33 | 24% | −3pp |
| Operating profit | 0.44 | 32% margin | +20pp |
| Other income, net | 0.04 | ||
| Tax | −0.06 | ||
| Net profit | 0.42 | 31% margin | +22pp |
394 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest